Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENTIDS 800.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus PENTIDS 800.
OMNIPEN (AMPICILLIN) vs PENTIDS '800'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), transpeptidases that catalyze the final transpeptidation step of peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
800 mg orally every 6 to 8 hours; maximum 4 g per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.5-1 hour; prolonged to 2-5 hours in renal impairment.
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal: ~60-85% unchanged via glomerular filtration and tubular secretion; Biliary: ~10%; Fecal: <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic